A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-07-22 and is reviewed periodically as new material appears.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
=== Nuclear === In addition to its reported mitochondrial function, some researchers have proposed a very small pool of active nuclear SIRT3 exists. This pool is reported to consist of the long form of SIRT3 and has been suggested to have histone deacetylase activity. The observation that SIRT3 has nuclear activity came from a report that SIRT3 protected cardiomyocytes from stress mediated cell death and that this effect was due to deacetylation of a nuclear factor, Ku-70.
Melo's government also became known for his large-scale program of the concession of programs and public spaces to private initiatives, saying that the privatization program "is in the DNA" of his government. It was put forth that the municipality did not have the conditions to maintain these services adequately and that the partnerships would bring qualified individuals to the system and health benefits for the population. During his electoral campaign, he declared that services should be public, but backed up by private partnerships. Places for the dispersion of the equipment included Auditório Araújo Viana, Teatro de Câmara Túlio Piva, Parque da Harmonia, and stretch 1 of the Orla do Guaíba, some of them completing a process started during the previous administration. They had expected new concessions at Farroupilha, Moinhos de Vento and Marinha do Brasil parks; from stretches 2 and 3 of the Orla do Guaíba; Hospital de Pronto Socorro and Hospital Materno-Infantil Presidente Vargas; the Usina do Gasômetro; with garbage collection and water and sewage treatment; green areas in the surrounding areas of the Aeromóvel and the area around the Joaquim Felizardo Museum of Porto Alegre. The public transport company Carris was privatized, with its assets being sold. The program came to be criticized for devaluing the public character of services and spaces, and to allow them to be exploited commercially, along with the program's proposals having little transparency and without the necessary dialogue with the community.
Fospropofol (INN), often used as the disodium salt (trade name Lusedra), is an intravenous sedative-hypnotic agent. It is currently approved for use in sedation of adult patients undergoing diagnostic or therapeutic procedures such as endoscopy.
Sources: en.wikipedia.org
=== Football clubs === In the 1960s, Inter Milan has its greatest period of success known as [La] Grande Inter ("Great Inter"), achieved when Helenio Herrera was their manager. He won seven trophies with the club. In 2004, Ferruccio Mazzola, Inter player during that period, accused him of distributing performance-enhancing drugs, including amphetamines, among the team players, especially the substitute players "who often served as guinea pigs for trying new pills and see if they worked." When he found out that some in the team were spitting them out, he dissolved them in coffee to make sure they were consumed, a practice known as Caffè di Herrera ("Herrera's Coffee"). In 2010, Inter sued Mazzola but lost the case, the court believed him. One of the reasons he spoke up were the serious medical conditions and/or deaths of some of his former members: Giuliano Taccola, then team's captain Armando Picchi (died aged 36 due to cancer), Marcello Giusti, Carlo Tagnin, Mauro Bicicli, Ferdinando Miniussi, Enea Masiero and Pino Longoni. He suspected the drugs to be the cause of their sufferings. in 2015, his brother Sandro, who denied everything at the beginning, admitted that the incidents happened. In the 1970s performance-enhancing drugs were used on a regular basis according to witnesses of that period, mostly in Ajax, Feyenoord and AZ Alkmaar during competitive matches, including the 1970 and 1972 Intercontinental Cups won by the first two cited clubs. Jan Peters recounted drug use before the big games. They seemed to work as he felt energy boosts and euphoria.
163 (4): 689–696. doi:10.1176/appi.ajp.163.4.689. PMID 16585445. Sciacca, K. (1997). "Peer Support for People Challenged by Dual Diagnosis: 'Helpful People in Touch' (Consumer Led Self-Help)" (PDF). In Mowbray, C.T.; Moxley, D.P.; Jasper, C.A.; Howell, L.L. (eds.). Consumers as Providers in Psychosocial Rehabilitation. IAPSRS Publisher. p. 82. Archived from the original (PDF) on 1 February 2012. Retrieved 2 September 2011. Adamson, Simon J.; Todd, Fraser C.; Douglas Sellman, J.; Huriwai, Terry; Porter, Joel (2006). "Coexisting Psychiatric Disorders in a New Zealand Outpatient Alcohol and other Drug Clinical Population". Australian & New Zealand Journal of Psychiatry. 40 (2): 164–170. doi:10.1080/j.1440-1614.2006.01764.x. PMID 16476135. S2CID 208628311.
Although often prevented and treatable if detected early, pressure ulcers can be very difficult to prevent in critically ill people, frail elders, and individuals with impaired mobility such as wheelchair users (especially where spinal injury is involved). Primary prevention is to redistribute pressure by regularly turning the person. The benefit of turning to avoid further sores is well documented since at least the 19th century. In addition to turning and re-positioning the person in the bed or wheelchair, eating a balanced diet with adequate protein and keeping the skin free from exposure to urine and stool is important. The rate of pressure ulcers in hospital settings is high; the prevalence in European hospitals ranges from 8.3% to 23%, and the prevalence was 26% in Canadian healthcare settings from 1990 to 2003. In 2013, there were 29,000 documented deaths from pressure ulcers globally, up from 14,000 deaths in 1990. The United States has tracked rates of pressure injury since the early 2000s. Whittington and Briones reported nationwide rates of pressure injuries in hospitals of 6% to 8%. By the early 2010s, one study showed the rate of pressure injury had dropped to about 4.5% across the Medicare population following the introduction of the International Guideline for pressure injury prevention. Padula and colleagues have witnessed a +29% uptick in pressure injury rates in recent years associated with the rollout of penalizing Medicare policies.
Sources: en.wikipedia.org
=== Chemical synthesis === The demand for vanilla flavoring has long exceeded the supply of vanilla beans. As of 2001, the annual demand for vanillin was 12,000 tons, but only 1,800 tons of natural vanillin were produced. The remainder was produced by chemical synthesis. Vanillin was first synthesized from eugenol (found in oil of clove) in 1874–75, less than 20 years after it was first identified and isolated. Vanillin was commercially produced from eugenol until the 1920s. Later it was synthesized from lignin-containing "brown liquor", a byproduct of the sulfite process for making wood pulp. Counterintuitively, though it uses waste materials, the lignin process is no longer popular because of environmental concerns, and today most vanillin is produced from guaiacol. Several routes exist for synthesizing vanillin from guaiacol. At present, the most significant of these is the two-step process practiced by Rhodia since the 1970s, in which guaiacol (1) reacts with glyoxylic acid by electrophilic aromatic substitution. The resulting vanillylmandelic acid (2) is then converted by 4-hydroxy-3-methoxyphenylglyoxylic acid (3) to vanillin (4) by oxidative decarboxylation.
Inactivation of estradiol includes conversion to less-active estrogens, such as estrone and estriol. Estriol is the major urinary metabolite. Estradiol is conjugated in the liver to form estrogen conjugates like estradiol sulfate, estradiol glucuronide and, as such, excreted via the kidneys. Some of the water-soluble conjugates are excreted via the bile duct, and partly reabsorbed after hydrolysis from the intestinal tract. This enterohepatic circulation contributes to maintaining estradiol levels. Estradiol is also metabolized via hydroxylation into catechol estrogens. In the liver, it is non-specifically metabolized by CYP1A2, CYP3A4, and CYP2C9 via 2-hydroxylation into 2-hydroxyestradiol, and by CYP2C9, CYP2C19, and CYP2C8 via 17β-hydroxy dehydrogenation into estrone, with various other cytochrome P450 (CYP) enzymes and metabolic transformations also being involved. Estradiol is additionally conjugated with an ester into lipoidal estradiol forms like estradiol palmitate and estradiol stearate to a certain extent; these esters are stored in adipose tissue and may act as a very long-lasting reservoir of estradiol.
==== Separation of unbound small molecules and ligand-protein complexes ==== Affinity selection is followed by the removal of unbound small molecules via ultrafiltration or size-exclusion chromatography, making only protein-bound ligands available for downstream analysis. Several types of ultrafiltration have been reported with varying degrees of throughput, including pressure-based, centrifugal, and precipitation-based ultrafiltration. Under both pressure-based and centrifugal formats, unbound small molecules are forced through a semipermeable membrane that excludes proteins on the basis of size. Multiple washing steps are required after ultrafiltration to ensure complete removal of unbound small molecules. Ultrafiltration can also be confounded by non-specific adsorption of unbound small molecules to the membrane. A group at the University of Illinois published a screening strategy involving amyloid-beta, in which ligands were used to stabilize the protein and prevent its aggregation. Ultrafiltration was used to precipitate aggregated amyloid-beta and remove unbound ligands, while the ligand-stabilized protein was detected and quantified using mass spectrometry. Size-exclusion chromatography (SEC) is more widely used in industrial drug discovery and has the advantage of more efficient removal of unbound compounds as compared to ultrafiltration. Size-exclusion approaches have been described in both high-performance liquid chromatography (HPLC) based and spin column formats.
Ions in a quadrupole field experience restoring forces that drive them back toward the center of the trap. The motion of the ions in the field is described by solutions to the Mathieu equation. When written for ion motion in a trap, the equation is
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.